We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
+3.34%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$82.3M
AUM Growth
-$16M
Cap. Flow
-$15.9M
Cap. Flow %
-19.33%
Top 10 Hldgs %
95.89%
Holding
22
New
6
Increased
5
Reduced
2
Closed
2

Top Buys

1
GARS
Garrison Capital Inc.
GARS
+$1.25M
2
ABDC
Alcentra Capital Corp
ABDC
+$530K
3
BBDC icon
Barings BDC
BBDC
+$445K
4
FSK icon
FS KKR Capital
FSK
+$247K
5
ACRS icon
Aclaris Therapeutics
ACRS
+$190K

Top Sells

1
TMH
Team Health Holdings Inc
TMH
+$335K
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$306K
3
INDP icon
Indaptus Therapeutics
INDP
+$31K

Sector Composition

1 Healthcare 75.58%
2 Financials 3.6%
3 Real Estate 1.74%
4 Consumer Discretionary 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SBBP
1
DELISTED
Strongbridge Biopharma plc.
SBBP
$40M 48.61%
5,514,994
– –
MTEM
2
DELISTED
Molecular Templates, Inc.
MTEM
$10.2M 12.35%
67,586
– –
KALA icon
3
KALA BIO
KALA
$14.4M
$10.1M 12.23%
218
– –
GARS
4
DELISTED
Garrison Capital Inc.
GARS
$8.11M 9.86%
1,000,000
+150,000
+18% +$1.25M
AGRX
5
DELISTED
Agile Therapeutics
AGRX
$4.9M 5.95%
910
– –
BRK.B icon
6
Berkshire Hathaway Class B
BRK.B
$1.06T
$1.77M 2.16%
8,945
– –
JBGS
7
JBG SMITH
JBGS
$867M
$1.43M 1.74%
41,170
+5,041
+14% +$166K
IWM icon
8
CALL
iShares Russell 2000 ETF
IWM
$82.2B
$997K 1.21%
+6,540
New +$982K
ONCT
9
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$799K 0.97%
449
– –
SPY icon
10
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$672K 0.82%
2,519
-74,533
-97% -$19.4M
ICMB icon
11
Investcorp Credit Management BDC
ICMB
$12.3M
$574K 0.7%
70,895
+9,036
+15% +$78K
ABDC
12
DELISTED
Alcentra Capital Corp
ABDC
$500K 0.61%
+59,562
New +$530K
ACRS icon
13
Aclaris Therapeutics
ACRS
$793M
$444K 0.54%
17,994
+7,818
+77% +$190K
BBDC icon
14
Barings BDC
BBDC
$890M
$385K 0.47%
+40,580
New +$445K
INDP icon
15
Indaptus Therapeutics
INDP
$337M
$375K 0.46%
32
-2
-6% -$31K
ADNT icon
16
Adient
ADNT
$1.55B
$373K 0.45%
4,737
– –
FSK icon
17
FS KKR Capital
FSK
$3.06B
$226K 0.27%
+7,677
New +$247K
MDGL icon
18
Madrigal Pharmaceuticals
MDGL
$12.8B
$222K 0.27%
+2,418
New +$138K
MRNS
19
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$152K 0.18%
4,661
+611
+15% +$16.5K
CPRX icon
20
Catalyst Pharmaceutical
CPRX
$129K 0.16%
+33,110
New +$109K
JAZZ icon
21
Jazz Pharmaceuticals
JAZZ
$15.5B
– –
-1,997
Closed -$306K
TMH
22
DELISTED
Team Health Holdings Inc
TMH
– –
-7,709
Closed -$335K

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q4 2017 Portfolio in Review

As of Q4 2017, Caxton Corporation held 22 positions worth $82.3M, down 16% from $98.2M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Caxton Corporation withdrew a net $15.9M in Q4 2017, closing 2 positions and reducing 2 holdings. Its most notable exit was Team Health Holdings Inc, an estimated $335K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 60% a quarter earlier, followed by Financials and Real Estate.

Against the trend, Caxton Corporation opened a new position in Alcentra Capital Corp worth $500K.

  • Caxton Corporation's largest Q4 2017 buy was Alcentra Capital Corp: 59,562 shares worth $500K.
  • Caxton Corporation added most to Garrison Capital Inc. in Q4 2017, an estimated $1.25M increase.
  • Caxton Corporation's biggest Q4 2017 reduction was Indaptus Therapeutics, cutting an estimated $31K.
  • Caxton Corporation fully exited Team Health Holdings Inc in Q4 2017, selling an estimated $335K.
  • Caxton Corporation's ten largest holdings make up 96% of its $82.3M portfolio in Q4 2017.
  • Caxton Corporation opened 6 new positions and closed 2 in Q4 2017.
  • Caxton Corporation's portfolio value fell 16% quarter-over-quarter to $82.3M.

Based on Caxton Corporation's 13F filing for Q4 2017, filed 14 Feb 2018.